Citadel Advisors
QNTM

Citadel Advisors’s Quantum Biopharma Class B Subordinate Voting Shares QNTM Stock Holding History

Citadel Advisors’s Portfolio QNTM Stock Details QNTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-260
Closed -$12.1K – 15623
2024
Q1 		$12.1K Sell
260
-57
-18% -$3.12K ﹤0.01% 13375
2023
Q4 		$18.9K Sell
317
-35
-10% -$2.46K ﹤0.01% 12661
2023
Q3 		$27.7K Buy
352
+140
+66% +$11.4K ﹤0.01% 12351
2023
Q2 		$15.9K Sell
212
-153
-42% -$13.1K ﹤0.01% 12921
2023
Q1 		$36.7K Sell
365
-363
-50% -$31.2K ﹤0.01% 12529
2022
Q4 		$37.3K Buy
728
+336
+86% +$18.6K ﹤0.01% 12497
2022
Q3 		$21K Sell
392
-219
-36% -$12.9K ﹤0.01% 12064
2022
Q2 		$31K Sell
611
-597
-49% -$35.8K ﹤0.01% 12209
2022
Q1 		$68K Sell
1,208
-70
-5% -$4.24K ﹤0.01% 12599
2021
Q4 		$86K Sell
1,278
-628
-33% -$54.5K ﹤0.01% 12863
2021
Q3 		$196K Buy
1,906
+512
+37% +$54.7K ﹤0.01% 12016
2021
Q2 		$159K Buy
1,394
+306
+28% +$35.5K ﹤0.01% 12431
2021
Q1 		$135K Sell
1,088
-66
-6% -$9.23K ﹤0.01% 12168
2020
Q4 		$118K Buy
1,154
+460
+66% +$54.3K ﹤0.01% 10114
2020
Q3 		$115K Buy
+694
New +$144K ﹤0.01% 9191

Other funds holding QNTM

AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
PTP
Platform Technology Partners New York $611M AUM 25.5% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
MG
Marex Group London $15.8B AUM 31.44% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
AUB
Atlantic Union Bankshares Glen Allen, Virginia $5.21B AUM 19.46% 1-Year Est. Return

Citadel Advisors's QNTM Position: Q1 2026 in Review

Citadel Advisors held its Quantum Biopharma Class B Subordinate Voting Shares (QNTM) position steady in Q1 2026 at 15,863 shares worth $76.6K. The position accounts for ﹤0.01% of the portfolio, ranked #12205.

Citadel Advisors first reported a position in QNTM in Q4 2020 and has held it in 10 quarters since. The position peaked at $154K in Q2 2021. 25 funds tracked by Wall St. Rank hold QNTM as of Q1 2026.

  • Citadel Advisors held 15,863 shares of Quantum Biopharma Class B Subordinate Voting Shares worth $76.6K as of Q1 2026.
  • Citadel Advisors left its Quantum Biopharma Class B Subordinate Voting Shares share count unchanged in Q1 2026.
  • Quantum Biopharma Class B Subordinate Voting Shares made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12205 holding.
  • Citadel Advisors first reported a position in Quantum Biopharma Class B Subordinate Voting Shares in Q4 2020 and has held it in 10 quarters since.
  • Citadel Advisors's Quantum Biopharma Class B Subordinate Voting Shares position peaked at $154K in Q2 2021.
  • 25 funds tracked by Wall St. Rank held Quantum Biopharma Class B Subordinate Voting Shares as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.